PALISADE BIO INC
For the period ended Dec 31, 2023. Filed Mar 26, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 26, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 16. Form 10-K Summary
None.
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized.
| PALISADE BIO, INC. | ||
| Date: March 26, 2024 | By: | /s/ J.D. Finley |
|---|---|---|
| J.D. Finley | ||
| Chief Executive Officer, Chief Financial Officer and Director | ||
POWER OF ATTORNEY
KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints J.D. Finley, as his true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution, for him and in his name, place, and stead, in any and all capacities, to sign any and all amendments to this Annual Report on Form 10-K, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as he might or could do in person, hereby ratifying and confirming that all said attorneys-in-fact and agents, or his or their substitute or substitutes, may lawfully do or cause to be done by virtue hereof.
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this Annual Report on Form 10-K has been signed below by the following persons on behalf of the Registrant in the capacities and on the dates indicated.
| Name | Title | Date |
|---|---|---|
| /s/ J.D. Finley | Chief Executive Officer, Chief Financial Officer and Director | March 26, 2024 |
| J.D. Finley | (Principal Executive and Financial Officer) | |
| /s/ Mitchell Jones, M.D., Ph.D. | Chief Medical Officer | March 26, 2024 |
| Mitchell Jones, M.D., Ph.D. | ||
| /s/ Donald A. Williams | Chairman of the Board of Directors | March 26, 2024 |
| Donald A. Williams | ||
| /s/ Binxian Wei | Director | March 26, 2024 |
| Binxian Wei | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.